Biennial mammography optimal screening interval for average risk women
the ONA take:
A comprehensive analysis of digital mammography tests has indicated that biennial (once every two years) screening is preferable for women of age 50 through 74 that have an average risk of developing breast cancer.
This screening frequency should offer a good balance between prudent detection and the risk of false-positive results.
The study findings indicated that biennial screening maintains an average of 81.2% of annual screening benefits with fewer false-positives; whereas annual screening, although it could avert 3 more cancer deaths, would yield approximately 1988 additional false-positive test results.
This study was a collaboration between six modeling research groups that belong to CISNET, the NCI-sponsored Cancer Intervention and Surveillance Modeling Network, coupled with investigators based at the Breast Cancer Surveillance Consortium (BCSC).
The paper's lead author was Jeanne S. Mandelblatt, MD, MPH, of Georgetown Lombardi Comprehensive Cancer Center (CISNET).
The modeling incorporated national data on breast cancer risk, treatment effects, and incidence of breast cancer; and reviewed one- and two-year screening intervals on individuals with varying starting ages. The research also considered digital screening and breast density factors.
Other modeling findings revealed that biennial screening during the age span of 50-74 would achieve a roughly 25% mortality reduction. Starting the biennial screening at age 40 averts an average of one additional cancer death but also generates an average of 576 additional false-positive tests.
The paper's lead author cautioned that these model findings should still not override a screening frequency determination based on individual factors, based on acceptance of false-positive results, over treatment, etc. She stated that screening frequency must be balanced against the risk of chemotherapy and/or radiation treatment that may not needed.
Biennial (once every two years) screening is preferable for women of age 50 through 74 that have an average risk of developing breast cancer.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|